# Study of Angiogenic Cell Therapy for Progressive Pulmonary Hypertension

> **NCT03001414** · PHASE2,PHASE3 · TERMINATED · sponsor: **Northern Therapeutics** · enrollment: 22 (actual)

## Conditions studied

- Hypertension,Pulmonary

## Interventions

- **BIOLOGICAL:** Placebo followed by Autologous EPCs transfected with human eNOS
- **BIOLOGICAL:** Autologous EPCs transfected with human eNOS followed by Placebo
- **BIOLOGICAL:** Autologous EPCs transfected with human eNOS

## Key facts

- **NCT ID:** NCT03001414
- **Lead sponsor:** Northern Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-09-28
- **Primary completion:** 2023-05-04
- **Final completion:** 2023-11-01
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** Lower than anticipated enrollment
- **Last updated:** 2025-01-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03001414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03001414, "Study of Angiogenic Cell Therapy for Progressive Pulmonary Hypertension". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03001414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*